Skip to main content

Table 2 Characteristics of the 22 patients treated with locally produced CKRT dialysate

From: Rapid implementation of an emergency on-site CKRT dialysate production system during the COVID-19 pandemic

 

No. (%) or Mean ± SD (Range)

Age (years)

51.3 ± 12.5 (26–74)

Female gender

2 (9.1%)

Weight (kg)

100.1 ± 33.2 (50.2–182.5)

IBW (kg)

71.5 ± 7.9 (57–85)

Height (cm)

176.6 ± 8.5 (160–191)

BMI (kg/m2)

31.8 ± 9.5 (19.0–57.7)

Indication for CKRT

 AKI

15 (68.2%)

 AKI on CKD

5 (22.7%)

 Chronic kidney failure

2 (9.1%)

Primary Admission Diagnosesa

 COVID-19

11 (50%)

 Sepsis/septic shockb

6 (27.3%)

 Stroke or ICH

4 (18.2%)

 Trauma/fall

3 (13.6%)

 Liver diseasec

2 (9.1%)

 Overdose/intoxication

1 (4.5%)

 Hemorrhagic shock

1 (4.5%)

 Cardiac Arrest

1 (4.5%)

 Rhabdomyolysis

1 (4.5%)

 Seizure

1 (4.5%)

Illness Severityd

 SOFA score

14.5 ± 2.4 (9–19)

 IMV

18 (81.8%)

 NIV

1 (4.5%)

 Vasopressor use

19 (86.4%)

 Length of hospital stay (days)

31.4 ± 22.9

  1. Abbreviations: AKI acute kidney injury, BMI body mass index, CKD chronic kidney disease, CKRT continuous kidney replacement therapy, IBW ideal body weight, ICH intracranial hemorrhage, IMV invasive mechanical ventilation, NIV non-invasive ventilation, SD standard deviation, SOFA sequential organ failure assessment
  2. aMultiple diagnoses were present in some patients
  3. bExcludes sepsis due to confirmed viral infection
  4. cIncludes end-stage liver disease and acute-on-chronic liver failure
  5. dData are from the 24 h prior to initial exposure to local dialysate whenever available; see Table 4 for additional details